Modified aptamers as reagents to characterize recombinant human erythropoietin products.

ABSTRACT: Reliable and reproducible monitoring of the conformational state of therapeutic protein products remains an unmet technological need. This need is amplified by the increasing number of biosimilars entering the drug development pipeline as many branded biologics are reaching the end of their market exclusivity period. Availability of methods to better characterize protein conformation may improve detection of counterfit and unlicensed therapeutic proteins. In this study, we report the use of a set of modified DNA aptamers with enhanced chemical diversity to probe the conformational state of 12 recombinant human erythropoietin (rHuEPO) therapeutic protein products; one FDA-licensed rHuEPO originator biological product, three rHuEPO products that are approved for marketing in the US or EU as

SUBMITTER: Jankowski W 

PROVIDER: S-EPMC7596557 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature